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Abstract: Background: Rising rates of obesity have been reported in patients with inflammatory
bowel disease (IBD); however, prospective data is lacking. The aim of this study is to prospectively
evaluate body composition in adults with IBD over 24 months. Methods: Whole body dual
energy X-ray absorptiometry (DXA) data was performed at 0 months, 12 months, and 24 months.
Bone mineral density (BMD), fat mass index (FMI (kg)/height (m2)), appendicular skeletal muscle
index (ASMI (kg)/height (m2)), visceral adipose tissue and the visceral adipose height index
(VHI, VAT area (cm3)/height (m2)), and clinical and anthropometric assessments were performed
at each time point. Multivariable linear mixed effects regression analyses were performed.
Results: Initially, 154 participants were assessed at baseline (70% Crohn’s disease, 55% male,
median age 31 years), of whom 129 underwent repeated DXA at 12 months, and 110 underwent
repeated DXA at 24 months. Amongst those undergoing repeated DXA, their body mass index
(BMI) significantly increased over time, such that by 24 months, 62% of patients were overweight
or obese (annual change BMI β = 0.43, 95%CI = [0.18, 0.67], p = 0.0006). Gains in BMI related to
increases in both FMI and VHI (β = 0.33, 95%CI = [0.14, 0.53], p = 0.0007; β = 0.08, 95%CI = [0.02, 0.13],
p = 0.001; respectively), whereas ASMI decreased (β = −0.07, 95%CI = [−0.12, −0.01], p = 0.01) with
a concordant rise in rates of myopenia (OR = 3.1 95%CI = [1.2, 7.7]; p = 0.01). Rates of osteopenia and
osteoporosis were high (37%), but remained unchanged over time (p = 0.23). Conclusion: Increasing
rates of obesity in patients with IBD coincide with decreases in lean muscle mass over time, while
high rates of osteopenia remain stable. These previously undocumented issues warrant attention in
routine care to prevent avoidable morbidity.
Keywords: body composition; obesity; visceral adipose tissue; fat; osteoporosis; osteopenia;
sarcopenia; inflammatory bowel disease
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1. Introduction
Body composition refers to proportions of bone, fat, and fat-free (lean) mass in the body and
may be abnormal in many patients with inflammatory bowel disease (IBD) [1]. Despite the potential
negative effects of disturbances in body composition on IBD-related outcomes, response to therapy,
cardiovascular disease, and quality of life (QoL), there is a paucity of prospective data on body
composition in patients with IBD [1,2].
Rates of obesity are rising in patients with IBD, as in the general population; 15–40% of adults
with IBD are obese, and 20–40% are overweight [3]. IBD may be an independent risk factor for obesity
that is driven by dysbiosis and aberrations in intestinal microbial metabolism [4,5]. Treatments used for
IBD, in particular corticosteroids and anti-tumor necrosis factor alpha therapies, may also play a role
in obesity [3]. On the other hand, adipose tissue is metabolically active, and could plausibly contribute
to a pro-inflammatory susceptibility to IBD [4,6]. However, existing data on the impact of obesity on
IBD susceptibility and disease course are conflicting. This is partly due to the use of the body mass
index (BMI) as a blunt instrument for measuring adiposity, which is unable to distinguish between
adiposity compartments with distinct metabolic profiles [3,6–10]. Visceral adipose tissue (VAT) is
increased in many patients with Crohn’s disease (CD) and has been associated with a complicated CD
phenotype [3,4,6,11–14]. There are no longitudinal prospective data on direct measures of adiposity in
patients with IBD.
There are emerging reports of high rates of both myopenia, which is defined as low lean mass,
and sarcopenia, which is defined as a low lean mass coupled with loss of strength, in patients with
IBD [1,15–17]. This matters, because low lean mass has been associated with an increased need for
surgery and poor surgical outcomes in IBD, as well as with osteopenia [18–20]. Lean mass deficits may
be difficult to detect in clinical practice, where BMI can be falsely reassuring [17,18]. Current data on
sarcopenia in IBD are limited by small sample sizes and retrospective study designs, as well as a lack
of an appropriate incorporation of a functional assessment [1].
A deficit in bone mineral density (BMD) (osteoporosis/osteopenia) is one of the most common
complications of IBD, and has been reported in 20% to 50% of patients [21–23]. Reduced BMD is associated
with an increased risk of pathological fractures and associated morbidity [22,24]. The pathogenesis of
metabolic bone disease in IBD is likely multifactorial; however, clinical data are lacking, and the influence
of IBD-related factors beyond conventional risk factors remains poorly explored [25,26].
Dual-energy X-ray absorptiometry (DXA) is in routine use in patients with IBD for the
measurement of BMD. Whole body DXA adds little in terms of time and radiation, yet gleans accurate
and regional body composition information and is considered a gold-standard tool for the evaluation
of body composition as compared to cross-sectional imaging [1,27].
Therefore, the aims of this study were:
1. To evaluate body composition in patients with IBD, with serial prospective measurements
over time;
2. To explore the influence of clinical factors on body composition in patients with IBD;
3. To explore whether standard anthropometric testing can detect aberrations in body composition.
2. Materials and Methods
2.1. Subjects
Consecutive patients with IBD (aged 18–50 years and pre-menopausal if female) managed by
a tertiary IBD service were invited to participate in a prospective study between April 2012 and
September 2013 (Figure 1). Those with significant medical or surgical comorbidity other than IBD,
current pregnancy, or steroid use other than that required for IBD, were excluded.
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Figure 1. CONSORT diagram—inflammatory bowel disease (IBD) cohort. Legend: DXA, dual energy 
X-ray absorptiometry, BMD, bone mineral density. 
2.2. Subject Data Collection 
Prospective data were captured at 0 months, 12 months, and 24 months. At each study time-
point case note, an IBD database and medical prescription review was undertaken. Data capture 
included demographics, Montreal classification at baseline, current IBD therapy, cumulative lifetime 
corticosteroid use (equivalent to prednisolone ≥10 mg/day) and IBD-related surgery [28]. IBD disease 
activity was assessed at each study time point using clinical indices and biomarkers of inflammation 
(C-reactive protein (CRP) and faecal calprotectin (FC) using a CALPRO® ELISA test). CRP ≥ 5 mg/L 
and/or FC ≥ 100 μg/g were considered consistent with active disease as a composite biomarker 
assessment.  
Lifestyle factors were assessed at 0 months, 12 months, and 24 months. Average alcohol 
consumption was dichotomised into <20 g/day versus ≥20 g/day. Habitual physical activity was 
assessed using a validated self-administered Short International Physical Activity Questionnaire 
(IPAQ), which approximates metabolic equivalents MET-minutes per week and allows stratification 
into low, medium, and high activity groups [29]. 
2.3. Body Composition, Anthropometric Assessment, and Nutritional Assessment 
Dual energy X-ray absorptiometry (DXA, General Electric Lunar Prodigy Vision bone 
densitometer (system DF + 13727; Encore version 13.60, Madison WI, USA)) of the lumbar spine, total 
femur, and whole body was used to evaluate BMD and body composition at 0 months, 12 months, 
and 24 months using standard protocols [30]. 
Standard calculations of fat and muscle body components were made from DXA data. 
Appendicular skeletal muscle (ASM) mass, which is considered functionally relevant lean mass, was 
calculated as the sum of the lean mass of the arms and legs (kg) [31]. The ASM index (ASMI) is the 
ASM mass in kg divided by the height in metres, squared [32]. Fat mass (FM) is the sum of the body 
fat mass (kg). The fat mass index (FMI) is calculated as FM in kg divided by height in metres, squared 
[32]. VAT was measured using CoreScan® analysis software, which correlates well with CT scan 
measurements [33]. VAT was measured in terms of volume (centimetres3), mass (grams), visceral 
adipose tissue/height index (VHI, VAT volume (cm3)/height in metres, squared), and VAT: 
subcutaneous adipose tissue (SAT) ratio. Height (m), weight (kg), waist circumference (cm), and hip 
circumference (cm) were measured at the time of the DXA and the waist–hip ratio (WHR) was 
calculated. 
World Health Organisation (WHO) standard categories for BMI were used: <18.5 kg/m2 
(underweight), 18.5–24.9 kg/m2 (normal weight), 25–29.9 kg/m2 (overweight), ≥30 kg/m2 (obese) [34]. 
Data from the Australian Bureau of Statistics National Health Survey 2014–2015 provided numerical 
comparisons with age and sex-matched Australian population for BMI and waist circumference [35]. 
Population-based, age and gender-matched normative data and standard deviation (SD) values from 
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X-ray absorptiometry, BMD, bone mineral density.
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2.3. Body Composition, Anthropometric Assessment, and Nutritional Assessment
Dual energy X-ray absorptiometry (DXA, General Electric Lunar Prodigy Vision bone densitometer
(system DF + 13727; Encore version 13.60, Madison WI, USA)) of the lumbar spine, total femur, and whole
body was used to evaluate BMD and body composition at 0 months, 12 months, and 24 months using
standard protocols [30].
Standard calculations of fat and muscle body components were made from DXA data. Appendicular
skeletal muscle (ASM) mass, which is considered functionally relevant lean mass, was calculated as
the sum of the lean mass of the arms and legs (kg) [31]. The ASM index (ASMI) is the ASM mass in
kg divided by the height in metres, squared [32]. Fat mass (FM) is the sum of the body fat mass (kg).
The fat mass index (FMI) is calculated as FM in kg divided by height in metres, squared [32]. VAT was
measured using CoreScan® analysis software, which correlates well with CT scan measurements [33].
VAT was measured in terms of volume (cm3), mass (grams), visceral adipose tissue/height index
(VHI, VAT volume (cm3)/height in metres, squared), and VAT: subcutaneous adipose tissue (SAT)
ratio. Height (m), weight (kg), waist circumference (cm), and hip circumference (cm) were measured at
the time of the DXA and the waist–hip ratio (WHR) was calculated.
World Health Organisation (WHO) standard categories for BMI were used: <18.5 kg/m2
(underweight), 18.5–24.9 kg/m2 (normal weight), 25–29.9 kg/m2 (overweight), ≥30 kg/m2 (obese) [34].
Data from the Australian Bureau of Statistics National Health Survey 2014–2015 provided numerical
comparisons with age and sex-matched Australian population for BMI and waist circumference [35].
Population-based, age and gender-matched normative data and standard deviation (SD) values from
the National Health and Nutritional Examination Survey (NHANES) were used to calculate the
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z-scores for ASMI and the fat mass index (FMI) [17,32]. WHO population-based, age and sex-matched
normative data of the lumbar spine and femur BMD were used to calculate BMD t-scores and
z-scores [36]. The lowest BMD t-score at either site was used to stratify patients as normal (>−1),
osteopenic (≤−1 >−2.5), or osteoporotic (≤−2.5).
Isometric handgrip strength was measured using a Jamar® Digital Hand Dynamometer,
representing a robust surrogate measure of whole body strength [31]. Grip strength z-scores were
calculated from population-based age and sex-matched normative data derived from healthy adult
controls [17].
Myopenia was defined as an ASMI ≥1 SD below the age and gender-matched ASMI mean [31].
Sarcopenia was defined using combined anatomical and functional criteria, as both ASMI and grip
strength >1 SD below the age and gender-matched means [31].
Nutritional assessment was performed at each study time point using clinical and laboratory
criteria, including albumin, vitamin D (automated chemiluminescent assay), calcium, haemoglobin,
iron studies, vitamin B12, and folate. Low vitamin D was defined as serum 25(OH) vitamin D level
<50 nmol/L.
2.4. Management during Prospective Study Period
The routine IBD care of enrolled subjects within the tertiary IBD service was consistent with
international guidelines (Figure 1) [37,38]. The protocolised management of bone health and nutrition
was undertaken during the study period. Oral vitamin D supplementation was recommended to
those with low levels (<50 nmol/L). All of the patients were advised to follow a calcium-rich diet and
engage in regular exercise. Patients who were found to be osteopenic (or at risk of osteopenia with
current corticosteroid use) were advised to take calcium supplementation (1000 mg/day) and oral
vitamin D supplementation (≥1000 IU/day). Patients found to be osteoporotic were referred to the
Endocrinology service for consideration of bisphosphonate therapy.
2.5. Ethical Considerations
The study was approved by the Royal Adelaide Hospital Research Ethics Committee (#120304).
Whole-body DXA does not confer significant additional radiation to standard BMD assessment.
Radiation safety reported that the total radiation dose per DXA study visit was 2.56 µSv.
2.6. Statistical Methods
Continuous outcomes are presented using means, standard deviations, medians, and interquartile
ranges (IQR), with categorical outcomes as counts and percentages, unless otherwise stated. The lack
of existing prospective data on body composition in IBD did not allow a formal power calculation.
The enrolment of 150 patients was considered sufficient to provide adequate power for multivariable
analysis, allowing for a dropout rate of 30% over the 24 months.
Change over time. Changes in disease activity, treatment, nutrition, and anthropometric and
body composition variables in individual patients who underwent repeated measures testing over
the 24-month study period were assessed using either linear or logistic mixed effects models,
where appropriate. The β coefficient describes the change in the body composition variable per
unit of time in the study (12 months). In all of the models, time since baseline assessment (years) was
the linear fixed effect, with random intercepts per individual. Compound symmetric and unstructured
variance–covariance were assumed for the linear and logistic models respectively. In all of the
models, residuals and random effect estimates were examined to ensure that the model distributional
assumptions appeared satisfied. As a consequence, VHI was log transformed. Missing data values
were not included in the analysis.
Assessment of factors associated with body composition. Linear mixed-effects models were
constructed to explore prospective clinical associations with serial assessments of BMI, FMI, VHI,
ASMI, and BMD (lumbar spine t-score) at 0 months, 12 months, and 24 months. Univariable models
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were constructed, followed by full multivariable models. We report β coefficients that describe the
change in the dependent variable per unit change in a covariate. Missing data were imputed with
cohort means. Significance was set at the 5% alpha level (two-sided). Analyses were performed on R
software v3.4.3 (R Studio, Boston, MA 02210, USA) using the nlme and lme4 packages.
3. Results
3.1. Subject Characteristics
Overall, 197 patients with IBD were assessed for eligibility during the study enrolment period
(April 2012–September 2013), 43 of whom were excluded (Figure 1). Initially, 154 patients were enrolled
in the study at baseline, of whom 129 (84%) completed the 12-month and 110 (71%) completed the
24-month study assessment. Cross-sectional analysis of the cohort at baseline has been previously
published (Supplementary Table S1) [17]. Only those patients who underwent repeated measures
(n = 129) were included in the primary analysis (Table 1).
In brief, 95 (74%) patients had CD, and 34 (26%) had ulcerative colitis (UC) (Table 1). The median
age of the cohort was 31 years (IQR 25–40), with a median IBD disease duration of 7.7 years (IQR
4.5–12.3). The cohort was predominantly Caucasian (n = 121, 94%). Active disease, defined by
composite biomarker assessment, was present in 65 patients (50%) at baseline. Prior to enrolment, 38/95
(40%) patients with CD and 1/34 (1%) patient with UC had undergone abdominal surgery. At baseline,
53 (41%) of patients were prescribed biologic therapy, the use of which increased over the study period
(59 (54%) patients were prescribed biologic therapy at 24 months, p = 0.004). Oral corticosteroid therapy
was currently prescribed for 38 (29%) patients, which significantly decreased over time (p < 0.0001).
Vitamin D levels were low in 52 (40%) of the patients at baseline, 50/52 (96%) of whom were prescribed
replacement therapy. Accordingly, there was a significant increase in vitamin D levels over the study
period (p = 0.01).
3.2. Baseline Body Composition
A detailed cross-sectional analysis of the body composition of this cohort at baseline (n = 137,
as enrolled until July 2013) has been previously published [17].
In brief, of those who underwent repeated measures testing (n = 129), the mean BMI at baseline
was 26.5 ± 5.1; with 33 (26%) patients classified as overweight and 30 (23%) patients classified as obese
(Table 2). Myopenia was evident in 24 (19%) patients, and functional sarcopenia was evident in 12 (9%)
patients. Low BMD was prevalent at baseline; with 45 (35%) patients classified as osteopenic and 3
(2%) patients classified as osteoporotic (48 (37%), with either osteopenia or osteoporosis).
3.3. Changes in Body Composition over 24 Months
Anthropometrics. BMI increased over the study period (annual change β = 0.43, 95%CI = [0.18,
0.67], p = 0.0006), as did the proportion of patients categorised as overweight and obese (at 24 months
31% overweight and 31% obese) (Table 2, Figure 2). Waist circumference increased over time (β = 1.4,
95%CI = [0.4, 2.3], p = 0.003), although no significant change in WHR was observed. Mean BMI,
waist circumference, and the proportions of people characterised as overweight or obese, were each
numerically higher in the IBD cohort compared to the Australian population stratified by age and
gender (Supplementary Table S2).
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Table 1. Clinical and Nutritional Characteristics of IBD Cohort over 24 Months.
Baseline 12 Months 24 Months ∆ p Value
Demographics
Patients (n, %) 129 (84%) 129 (84%) 110 (71%) -
Male (n, %) 75 (58%) 75 (58%) 62 (58%) -
Age (years) (median, IQR) 31 (25–40) 32 (26–41) 33 (27–42) -
IBD phenotype
Crohn’s disease (n, %) 95 (74%) 92 (71%) 79 (72%)
Ulcerative colitis (n, %) 34 (26%) 37 (29%) 28 (25%)
IBD-related abdominal surgery (n, %) 39 (30%) 7 (5%) 12 (11%) -
IBD-related hospitalisation (n, %) - 22 (17%) 12 (11%) -
IBD Disease Activity
IBD clinical disease activity score -
Crohn’s Disease CDAI Mean ± SD 90 ± 99 71 ± 67 65 ± 58
Median, IQR 60 (26–126) 62 (26–110) 49 (20–90)
Ulcerative colitis partial Mayo mean ± SD 1.5 ± 2.2 1.4 ± 2.2 1.5 ± 1.9




8.7 ± 21 5.2 ± 11 5.3 ± 8
Median, IQR 1.7 (0.5–7.7) 1.9 (0.5–5.8) 1.6 (0.4–6.3)
Faecal calprotectin (µg/g) 0.49
Mean ± SD
Median, IQR
247.5 ± 305 155.9 ± 206 179.4 ± 227
84 (20–450) 50 (20–205) 93 (20–245)
Composite disease activity assessment §
(n active disease, %)
-
65 (50%) 59 (46%) 57 (52%
IBD Therapy
Oral corticosteroids ˆ Current (n, %) 38 (29%) 11 (9%) 7 (6%) <0.0001 *
Duration usage (mths) Mean ± SD 28 ± 57
Median, IQR 6 (1-24)
Biologic therapy overall (n, %) 53 (41%) 63 (49%) 59 (54%) 0.0004 *
Infliximab (n, %) 35 (27%) 41 (32%) 35 (32%)
Adalimumab (n, %) 16 (12%) 19 (15%) 22 (20%)
Vedolizumab (n, %) 2 (2%) 3 (2%) 2 (2%)
5-aminosalicylic acid therapy (n, %) 55 (43%) 58 (45%) 53 (48%) 0.18
Immunomodulator therapy Overall (n, %) 73 (57%) 78 (60%) 67 (61%) 0.12
Azathioprine (n, %) 46 (36%) 47 (36%) 41 (37%)
Mercaptopurine (n, %) 6 (5%) 6 (5%) 5 (5%)
Methotrexate (n, %) 3 (2%) 5 (3%) 4 (4%)
Thiopurine/allopurinol (n, %) 18 (14%) 20 (16%) 17 (15%)
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Table 1. Cont.
Baseline 12 Months 24 Months ∆ p Value
Exercise (IPAQ) ¶
Continuous Mean ± SD 4385 ± 5908 5570 ± 8952 4935 ± 6879 0.36
Median, IQR 2284 (693–5690) 2106 (862–5745) 2445 (942–5558)
Categorical Inactive 50 (39%) 47 (36%) 37 (34%)
Minimally active 30 (23%) 24 (19%) 23 (21%)
Active 28 (22%) 41 (32%) 35 (32%)
Nutritional assessment
Albumin (g/dL) Mean ± SD 40 ± 4.6 40 ± 3.8 40 ± 3.5 0.64
Median, IQR 40 (37–43) 40 (37–42) 40 (38–42)
Haemoglobin (g/L) Mean ± SD 141 ± 15 141 ± 14 143 ± 13 0.07
Median, IQR 141 (132–150) 141 (130–149) 144 (136–152)
Ferritin (ng/mL) Mean ± SD 87 ± 85 93 ± 122 115 ± 186 0.09
Median, IQR 62 (34–106) 63 (35–104) 71 (42–123)
Calcium Mean ± SD 2.35 ± 0.11 2.34 ± 0.1 2.34 ± 0.09 0.16
Median, IQR 2.35 (2.28–2.42) 2.36 (2.29–2.4) 2.34 (2.30–2.4)
Vitamin D (nmol/mL) # Mean ± SD 64 ± 28 65 ± 25 70 ± 25 0.01 *
Median, IQR 63 (41–84) 65 (48–80) 67 (53–85)
Low Vitamin D level 52 (40%) 40 (31%) 38 (35%)
Vitamin D supplementation 50 (39%) 40 (31%) 37 (34%)
Bisphosphonate therapy 2 (1%) 4 (3%) 4 (4%)
Analysis performed using linear and logistic mixed effects regressions. Data presented as mean ± standard deviation (SD), median (interquartile range (IQR)), counts and percentage.
CDAI, Crohn’s Disease Activity Index; § C-reactive protein (CRP) ≥5 mg/L and/or faecal calprotectin (FC) ≥100 µg/g were considered consistent with active disease as a composite
biomarker assessment. ˆ Cumulative months equivalent to prednisolone ≥10 mg daily. ¶ International Physical Activity Questionnaire (Short). # Low Vitamin D level classified as
<50 nmol/L, Vitamin D supplementation (≥1000 IU/day), * significant p value < 0.05.
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Table 2. Body composition in IBD patients over 24 months.
Body Composition Baseline (n = 129) Year 1 (n = 129) Year 2 (n = 110) p Value
Anthropometric assessment
Body mass index (BMI) Mean ± SD (kg/m2) 26.5 ± 5.1 27.4 ± 5.8 27.7 ± 5.6 0.0006 *
∆ ± SD - 0.52 ± 2.51 0.84 ± 2.66
Median (IQR) 25.1 (22.9–29.7) 26.5 (23.2–30.7) 26.8 (23.8–30.8)
BMI categorical ¶ Underweight < 18.5 4 (3%) 3 (2%) 3 (3%) 0.0006 *
Normal 18.5–25 58 (45%) 47 (36%) 38 (35%)
Overweight 25–30 33 (26%) 38 (29%) 34 (31%)
Obese ≥ 30 30 (23%) 35 (27%) 34 (31%)
Waist circumference (cm) Mean ± SD 90.8 ± 15.9 92.4 ± 14.5 94.1 ± 14.4 0.003 *
∆ ± SD - 0.73 ± 10.32 2.26 ± 9.18
Median (IQR) 88 (80–101) 91 (81–102) 93 (83–103)
Waist:hip ratio Mean ± SD 0.88 ± 0.11 0.88 ± 0.10 0.89 ± 0.10 0.31
∆ ± SD - −0.004 ± 0.11 0.01 ± 0.12
Median (IQR) 0.86 (0.81–0.95) 0.87 (0.82–0.92) 0.89 (0.83–0.94)
Grip strength (PSI) Mean ± SD 40.2 ± 12.0 39.5 ± 12.2 39.8 ± 12.4 0.68
∆ ± SD - −0.48 ± 5.56 −0.30 ± 5.01
Median (IQR) 37.8 (30.0–50.0) 38.0 (29.0–49.3) 37.4 (31.1–49.1)
Grip strength z-score Mean ± SD −0.63 ± 1.30 −0.9 ± 1.49 −0.67 ± 1.23 0.46
∆ ± SD - −0.27 ± 1.55 −0.01 ± 1.27
Median (IQR) −0.48 (−1.29–0.15) −0.75 (−1.41–0.12) −0.6 (−1.32–0.15)
Fat mass index (FMI)
(kg/height m2)
FMI (kg/m2) Mean ± SD 8.83 ± 4.57 9.07 ± 4.50 9.64 ± 4.59 0.0007 *
∆ ± SD - 0.26 ± 1.54 0.70 ± 2.05
Median (IQR) 7.67 (5.67–10.60) 8.09 (6.07–11.32) 8.61 (5.82–11.81)
FMI z-score Mean ± SD 0.24 ± 1.26 0.30 ± 1.26 0.42 ± 1.24 0.006 *
∆ ± SD - 0.06 ± 0.48 0.17 ± 0.61
Median (IQR) −0.13 (−0.59–0.93) 0.08 (−0.57–0.89) 0.25 (−0.47–1.15)
Visceral adipose tissue (VAT)
VAT volume (cm3) Mean ± SD 834.2 ± 821.7 903.9 ± 901.6 949.9 ± 826.7 0.01 *
∆ ± SD - 67.8 ± 331.8 102.1 ± 376.6
Median (IQR) 493.7 (216.9, 1175.9) 600.5 (248.8, 1291) 702.1 (266.6–1354)
VAT (grams) ˆ Mean ± SD 786.9 ± 775.2 852.76 ± 850.53 896.09 ± 779.94 0.01 *
∆ ± SD - 64.0 ± 313.0 96.3 ± 355.3
Median (IQR) 465.74 (204.59–1109.38) 566.51 (241.63–1209.85) 662.35 (256.23–1274.44)
VAT:SAT ˆ Mean ± SD 0.64 ± 0.68 0.64 ± 0.55 0.63 ± 0.49 0.36
∆ ± SD - −0.005 ± 0.50 0.026 ± 0.585
Median (IQR) 0.45 (0.24–0.8) 0.46 (0.31–0.83) 0.49 (0.28–0.89)
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Table 2. Cont.
Body Composition Baseline (n = 129) Year 1 (n = 129) Year 2 (n = 110) p Value
Visceral adipose tissue (VAT)
VHI ˆ Mean ± SD 0.26 ± 0.25 0.28 ± 0.28 0.3 ± 0.25 0.01 *
∆ ± SD - 0.022 ± 0.10 0.127 ± 0.604
Median (IQR) 0.15 (0.07–0.35) 0.2 (0.08–0.41) 0.23 (0.1–0.41)
Bone mineral density (BMD)
WHO t-score femur Mean ± SD −0.18 ± 1.02 −0.1 ± 1.03 −0.13 ± 1.03 0.001 *
∆ ± SD - 0.075 ± 0.191 0.081 ±0.266
Median (IQR) −0.21 (−0.96–0.52) −0.20 (−0.99–0.55) −0.17 (−0.97–0.69)
WHO t-score spine Mean ± SD −0.35 ± 1.1 −0.29 ± 1.11 −0.38 ± 1.17 0.47
∆ ± SD - 0.033 ± 0.34 0.027 ± 0.357
Median (IQR) −0.48 (−1.06–0.4) −0.37 (−1.05–0.39) −0.36 (−1.21–0.33)
WHO z-score femur Mean ± SD −0.16 ± 1.06 −0.11 ± 1.03 −0.19 ± 0.93 0.86
∆ ± SD - 0.049 ± 0.31 0.007 ± 0.52
Median (IQR) −0.24 (−0.93–0.46) −0.14 (−0.90–0.51) −0.12 (−0.91–0.48)
WHO z-score spine Mean ± SD −0.46 ± 1.08 −0.47 ± 1.09 −0.62 ± 1.14 0.51
∆ ± SD - 0.004 ± 0.385 −0.025 ± 0.41
Median (IQR) −0.52 (−1.19–0.29) −0.52 (−1.22–0.23) −0.58 (−1.4–0.18)
Bone status # Osteopenia (n, %) 45 (35%) 41 (32%) 37 (34%) 0.23
Osteoporosis (n, %) 3 (2%) 2 (2%) 3 (3%)
Overall osteopenia/porosis (n, %) 48 (37%) 43 (34%) 40 (37%)
Appendicular skeletal muscle
index (ASMI) (kg/height m2)
ASMI (kg/m2) Mean ± SD 7.76 ± 1.40 7.80 ± 1.45 7.68 ± 1.40 0.01 *
∆ ± SD - 0.014 ± 0.49 −0.127 ± 0.55
Median (IQR) 7.60 (6.57–8.48) 7.84 (6.74–8.62) 7.64 (6.66–8.45)
ASMI z-score Mean ± SD −0.21 ± 0.96 −0.21 ± 0.98 −0.32 ± 0.99 0.002 *
∆ ± SD - −0.006 ± 0.392 −0.0129 ± 0.444
Median (IQR) −0.31 (−0.95–0.17) −0.3 (−0.88–0.24) −0.45 (−0.93–0.29)
Myopenia (Low ASMI §) 24 (19%) 25 (19%) 25 (23%) 0.01 *
Functional sarcopenia
(Low ASMI AND low grip strength §) 12 (9%) 21 (16%) 17 (15%) 0.05
Table Legend: Reported are baseline distributions and change from baseline at 12 months and 24 months. Statistical analysis performed using linear and logistic mixed effects regressions.
Data presented as mean ± standard deviation, median (interquartile range), counts, and percentage. SD, standard deviation; ˆ Data log-transformed prior to analysis: ˆ VAT, visceral
adipose tissue; ˆ VAT:SAT, visceral adipose tissue: subcutaneous adipose tissue ratio; VHI, visceral adipose tissue area (cm3) divided by height (m2); § Low appendicular skeletal muscle
index (ASMI) and grip strength defined as ≥1 standard deviation below mean. ∆, mean difference from baseline at Year 1 and Year 2 (±standard deviation). # BMI categories and bone
status according to World Health Organisation criteria; * significant p value < 0.05.
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Figure 2. BMI and measures of adiposity in patients with IBD over 24 months. Figure Legend:
(A) Body mass index (BMI) categories according to World Health Organisation criteria; (B) Fat mass
index (kg/height m2). Mean and standard deviation presented; (C) Visceral adipose tissue (VAT)
height index (VAT volume cm3 /height m2). Mean and standard deviation presented. * p < 0.05,
denoting statistical significance.
Adiposity. FMI increased significantly over the study period (β = 0.33, 95%CI = [0.14, 0.53]
p = 0.0007), with a concordant increase in FMI z-score (β = 0.08, 95%CI = [ 02, 0.14], p = 0.006).
(Tab e 2, Figures 2 and 3) Similarly, VAT volume increased (β = 0.08, 95%CI = [0.02, 0.14], p 0.01)
which resulted in an increase in VHI (β = 0.08, 95%CI = [0.02, 0.13], p = 0.01), but not VAT:SAT
(β = 0.027, 95%CI = [−0.032, 0.087], p = 0.36) (Table 2).
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Muscle. ASMI decreased significantly over the study period (ASMIβ=−0.07, 95%CI = [−0.12, −0.01],
p = 0.01; ASMI z-score β = −0.07, 95%CI = [−0.11, −0.02], p = 0.002) (Table 2). There was a significant
increase in myop nia over the study period (19%, 19%, and 24% at 0 months, 12 months, and 24 months,
respe tively; OR = 3.1 95%CI = [1.2, 7.7]; p = 0.01) (Figure 4). There was a trend towards an in rease in the
proportion of patients classified as sarcopenic; however, this did not reach statistical significance (OR = 2.4,
95%CI = [1.0, 6.0]; p = 0.05).
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Figure 4. Myopenia, sarcopenia, and metabolic bone disease in patients with IBD over 24 months.
Figure Legend: (A) Sarcopenia defined as BOTH appendicular skeletal muscle index (ASMI) and
grip strength <1 standard deviation below gender and age-matched mean. Myopenia defined as
appendicular skeletal muscle index (ASMI) <1 standard deviation below gender and age-matched
mean; (B) osteopenia and osteoporosis according to World Health Organisation criteria. Osteopenia
defined as bone mineral density (BMD) 1–2.5 standard deviations and osteoporosis as ≥2.5 standard
deviations below the young adult mean. * p < 0.05, denoting statistical significance; ns, non-significant
p value > 0.05.
Bone. Femur BMD t-score increased significantly over the study period, but there was no
change in lumbar spine BMD t-score (β = 0.041, 95%CI = [0.016, 0.066], p = 0.001; β = 0.013,
95%CI = [−0.022, 0.048], p = 0.47, respectively). No difference in BMD z-scores at either site was
detected over time (Table 2). Overall, there was no significant change in the proportion of patients
classified with osteopenia 37/110 (34%) or osteoporosis 3/110 (3%) (p = 0.23), despite the proactive
management of bone health over the study period (Figure 4).
3.4. Clinical Associations with Serial BMI Measurements
BMI was positively associated with vitamin D levels (β = 0.006, 95%CI = [0.00, 0.0.11], p = 0.03). FMI,
ASMI, and grip strength were also positively associated with BMI over time (β = 1.0, 95%CI = [1.0, 1.1],
p < 0.0001; β = 1.3, 95%CI = [1.1, 1.5], p < 0.0001; β = 0.028, 95%CI = [0.008, 0.049], p = 0.006, respectively)
(Table 3).
3.5. Clinical Associations with Serial FM and VAT Measurements
Older age was positively associated with VHI (β = 0.040, 95%CI = [0.023, 0.057], p < 0.0001)
(Supplementary Tables S3 and S4). Male gender was positively associated with VHI, but negatively
associated with FMI (β = 0.67, 95%CI = [0.39, 0.95], p < 0.0001; β = −2.2, 95%CI = [−2.8, −1.6],
p < 0.0001, respectively). Serum vitamin D was negatively associated with FMI (β = −0.007,
95%CI = [−0.013, −0.001], p = 0.02, p = 0.02).
Anthropometric measures (BMI and waist circumference) were associated with a higher FMI
(β = 0.52, 95%CI = [0.45, 0.59], p < 0.0001; β = 0.07, 95%CI = [0.04, 0.10], p < 0.0001, respectively) and
VHI (β = 0.08, 95%CI = [0.06, 0.11], p < 0.0001; β = 0.015, 95%CI = [0.005, 0.026], p = 0.003 respectively).
In contrast, grip strength was negatively associated with FMI (β = −0.044, 95%CI = [−0.066, −0.021],
p < 0.0001).
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Table 3. Clinical associations with serial body mass index (BMI) measurements over 24 months.
Variable
Univariable Full Multivariable Model
Est. (95%CI) p Value Est. (95%CI) p Value
Time Repeated measures over 24 m 0.43 [0.21, 0.65] <0.0001 0.08 [−0.08, 0.24] 0.28
Demographics Age at study entry 0.24 [0.15, 0.33] <0.0001 0.021 [−0.004, 0.046] 0.08
Gender
(Male vs. female) 0.0 [−2.0, 2.0] 0.99 0.38 [−0.18, 0.95] 0.17
IBD-related factors
IBD phenotype (Ulcerative colitis vs. Crohn’s disease) −0.7 [−2.9, 1.5] 0.52 −0.04 [−0.46, 0.38] 0.86
IBD disease duration 0.014 [0.005, 0.022] 0.002 0.0003 [−0.0020, 0.0026] 0.78
Faecal calprotectin (µg/g) −0.0015 [−0.0025, 0.004] 0.007 0.00021 [−0.00044, 0.00086] 0.48
C-reactive protein (mg/L) −0.011 [−0.027, 0.006] 0.19 0.001 [−0.009, 0.011] 0.85
Current corticosteroid use −0.4 [−1.0, 0.2] 0.22 −0.10 [−0.49, 0.29] 0.55
Biologic therapy 0.25 [−0.31, 0.81] 0.38 0.04 [−0.18, 0.25] 0.69
Immunomodulator therapy 0.42 [−0.03, 0.88] 0.06 0.11 [−0.02, 0.23] 0.08





2.0 [−0.4, 4.4] 0.23
−0.24 [−0.75, 0.28]
0.34 [−0.11, 0.78] 0.07
Excess alcohol intake ˆ 0.2 [−4.9, 5.3] 0.95 0.8 [−0.1, 1.8] 0.06
Vitamin D level (nmol/mL) 0.006 [−0.005, 0.017] 0.25 0.006 [0.000, 0.011] 0.03
Habitual exercise (IPAQ score, continuous) § 0.002 [−0.036, 0.041] 0.91 0.009 [−0.011, 0.029] 0.36
Albumin (g/dL) 0.06 [−0.02, 0.13] 0.16 0.008 [−0.034, 0.049] 0.76
Body composition factors
Fat mass index (FMI) 1.1 [1.0, 1.2] <0.0001 1.0 [1.0, 1.1] <0.0001
Appendicular skeletal muscle index (ASMI) 2.1 [1.8, 2.5] <0.0001 1.3 [1.1, 1.5] <0.0001
Functional sarcopenia ¶ −1.5 [−2.5, −0.4] 0.0006 0.11 [−0.41, 0.62] 0.65
Grip strength (pounds per square inch, PSI) 0.024 [−0.024, 0.072] 0.32 0.028 [0.008, 0.049] 0.006
ˆ Data log-transformed prior to analysis: ˆ VAT, visceral adipose tissue; ˆ VAT:SAT, visceral adipose tissue: subcutaneous adipose tissue ratio; VHI, visceral adipose tissue area (cm3)
divided by height (m2); ¶ Low ASMI and grip strength ≥1 standard deviation below mean. ˆ Excess alcohol use defined according to the Australian Healthy Drinking Guidelines;
§ IPAQ, International Physical Active Questionnaire; FMI, fat mass index (kg/height m2); ASMI, appendicular skeletal muscle index (kg/height m2); Linear mixed effects regression
models with missing data imputed with cohort means.
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3.6. Clinical Associations with Serial ASMI Measurements
Male gender was associated with a higher ASMI (β= 1.2, 95%CI = [0.9, 1.4], p < 0.0001) (Supplementary
Table S5). FC was negatively associated with ASMI (β = −0.00043, 95%CI = [−0.00067, −0.00018],
p = 0.0004), whereas anthropometric measures, BMI, and grip strength were positively associated with
ASMI (β = 0.13, 95%CI = [0.11, 0.15], p < 0.0001; β = 0.020, 95%CI = [0.011, 0.028], p < 0.0001, respectively).
3.7. Clinical Associations with Serial BMD Measurements
IBD disease duration was negatively associated with lumbar spine t-score (β = 0.0031,
95%CI = [−0.0057, −0.0005], p = 0.01), as was grip strength (β = 0.009, 95%CI = [0.002, 0.017], p = 0.01)
(Supplementary Table S6). Both biologic therapy and corticosteroids (cumulative use) were associated
with increase lumbar spine t-scores (β = 0.08, 95%CI = [0.01, 0.16], p = 0.02; β = 0.10, 95%CI = [0.01, 0.18],
p = 0.02; respectively). Neither IBD phenotype nor vitamin D level was associated with changes in the lumbar
spine t-score.
4. Discussion
This prospective study has demonstrated persistent and progressive disturbances in body
composition in people with IBD over a relatively short time frame. The most striking finding was
a significant increase in the proportion of patients classified as overweight and obese, driven by
gains in adiposity. Conversely, muscle mass decreased, with a concordant rise in rates of myopenia.
Despite the proactive management of bone health, rates of osteopenia remained high and unchanged.
Abnormal body composition may go frequently unrecognised in clinical practice using BMI alone,
leaving patients with IBD at risk of potentially avoidable morbidity.
After 24 months of follow-up, 62% of patients with IBD were overweight or obese despite a
median age of just 33 years, which is numerically higher than age and gender- matched Australian
population data [35]. Earlier studies of obesity in IBD have failed to take into account direct measures
of adiposity [3,10]. This study demonstrates that gains in BMI were associated with significant
increases in both overall FM and VAT. VAT is a strong independent predictor of incident cardiovascular
disease after adjustment for clinical risk factors, including BMI [39,40]. Similar to to other chronic
inflammatory conditions, there is emerging evidence to suggest that patients with IBD are at increased
risk of cardiovascular disease, which is now recognised as a prime cause of morbidity in this young
demographic [2,41].
How can a link between IBD and obesity be explained? In contrast to retrospective reports,
we found no association between measures of adiposity and IBD phenotype, inflammatory burden,
or medications over time [3,6–10]. The lack of correlation between obesity and IBD therapy, in particular
cumulative corticosteroid use is surprising, yet may be in part accounted for by the significant decrease
in rates of corticosteroid use over the study period. Interestingly, serum vitamin D levels were
negatively associated with FMI, which may be related to the sequestration of vitamin D in adipose
tissue, coupled with lifestyle factors associated with obesity (less outdoor activity) [42]. The majority
of patients were classified as either inactive or minimally active, which is likely reflective of the
burden of chronic illness in this cohort, yet this was not shown to be associated with BMI. It is
possible that dysbiosis in IBD, which is characterised by reduced microbial diversity and an altered
microbial metabolic profile, is a predisposing factor to obesity [43–45], but this is speculation despite
gut metabolomic associations with post-prandial glucose [43–46].
While adiposity increased, muscle mass (ASMI) decreased. FC, as a measure of luminal inflammation
in IBD, was negatively associated with ASMI, which is consistent with the known catabolic effects of
chronic inflammation [18,20,47]. Lean mass is important in patients with IBD, and has been shown to
have a bearing on response to therapy, surgical outcomes, and quality of life [15,18,20,48,49]. Grip strength
proved to be a simple anthropometric test that was independently and positively associated with ASMI,
while also negatively associated with FMI.
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IBD disease duration was shown to be negatively associated with BMD; however, inflammation was not
associated with BMD over time, which is consistent with existing data showing a minimal impact of
IBD-related inflammation on longitudinal bone loss [21,23,25,26,50]. Likewise, vitamin D levels were
not associated with BMD, which is similar to other studies showing an uncertain benefit of vitamin D
supplementation on BMD in IBD patients [21,23,25,26,50]. Biologic therapy was found to be positively
associated with BMD over time, which is in line with current data [50,51]. The positive association
between corticosteroid use and BMD is surprising, and may be a spurious result due to multiple
comparisons. Nevertheless, rates of osteopenia remained high in this cohort, despite not only protocolised
management of bone health, but also a warm climate and readily accessible dairy products.
The limitations of this study are the relatively small sample size, which may have limited
statistical power. The study was neither structured nor powered to evaluate the influence of body
composition on hospitalisation or surgery over time, nor could it evaluate the impact of these factors
on body composition. It did not account for dietary intake, nor were other factors associated with
cardiometabolic risk measured (cholesterol, family history, blood pressure). Although a control group
was not included, the findings were compared to population-based data [35]. The predominantly
Caucasian cohort, which was derived from a single tertiary IBD referral centre, may also limit the
generalisability of the findings. On the other hand, it is the first prospective study that has incorporated
serial measures of body composition in IBD. Furthermore, DXA, in routine use for measuring BMD,
is an affordable tool for monitoring body composition, adding little to the time or radiation of the
test [21,33].
This study illustrates the rising rates of obesity in patents with IBD over time, driven by gains
in fat mass, while lean mass decreases and metabolic bone disease remains unchanged. Apart from
raising concerns about the cardiometabolic risk profile of patients with IBD, it is important that
clinicians recognise that an increase in BMI may obscure a decrease in muscle mass (myopenia).
The study provides a rationale for measuring body composition, as well as a means to do so with DXA,
and supports recommendations for the use of grip strength as a discriminatory anthropometric test in
clinical practice.
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